Research programme: HSP90 heat-shock protein inhibitors - Synta Pharmaceuticals

Drug Profile

Research programme: HSP90 heat-shock protein inhibitors - Synta Pharmaceuticals

Alternative Names: STA-12-1474; STA-1474

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synta Pharmaceuticals
  • Class Triazoles
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 22 Jul 2016 Synta Pharmaceuticals has been acquired and merged into Madrigal Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top